Latest Ratios: P/E Ratio 12.1x · EV/EBITDA 5.6x · ROE -44.4%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.7B | $3.8B | $3.6B | $2.0B | $523M | $1.4B | — | — |
| Enterprise Value | $5.4B | $1.4B | $2.3B | $457M | $-737908447 | $301M | — | — |
| P/E Ratio → | 12.08 | — | 140.44 | — | — | — | — | — |
| P/S Ratio | 0.44 | 0.32 | 0.39 | 0.35 | 0.13 | 0.73 | — | — |
| P/B Ratio | 7.98 | 3.84 | 3.52 | 2.52 | 0.59 | 1.01 | — | — |
| P/FCF | 1.89 | 3.56 | 3.76 | — | 1.49 | — | — | — |
| P/OCF | 7.07 | 3.44 | 3.65 | — | 1.37 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.12 | 0.26 | 0.08 | -0.18 | 0.16 | — | — |
| EV / EBITDA | 5.62 | — | 26.23 | — | — | — | — | — |
| EV / EBIT | — | — | 41.03 | — | — | — | — | — |
| EV / FCF | — | 1.35 | 2.47 | — | -2.10 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.4% | 14.4% | 20.1% | 20.8% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -3.4% | -3.4% | 0.6% | -4.0% | -14.8% | -29.7% | -68.8% | -46.8% |
| Net Profit Margin | -3.8% | -3.8% | 0.3% | -4.6% | -14.7% | -29.8% | -69.0% | -47.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -44.4% | -44.4% | 2.8% | -31.9% | -53.1% | -1185.2% | — | — |
| ROA | -7.9% | -7.9% | 0.6% | -6.7% | -15.4% | -20.5% | -22.5% | -19.4% |
| ROIC | — | — | — | — | — | -148.3% | — | — |
| ROCE | -25.3% | -25.3% | 2.1% | -8.8% | -37.4% | -48.4% | -22.4% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.44 | 0.29 | 0.37 | 0.33 | — | — | — |
| Debt / EBITDA | — | — | 3.35 | — | — | — | — | — |
| Net Debt / Equity | — | -2.39 | -1.21 | -1.95 | -1.41 | -0.79 | — | — |
| Net Debt / EBITDA | — | — | -13.73 | — | — | — | — | — |
| Debt / FCF | — | -2.21 | -1.29 | — | -3.59 | — | -3.28 | — |
| Interest Coverage | -23.85 | -23.85 | 2.41 | -9.86 | -25.97 | -119.89 | -114.48 | — |
Net cash position: cash ($2.8B) exceeds total debt ($430M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.95 | 0.95 | 0.90 | — | 1.40 | 1.71 | — | — |
| Quick Ratio | 0.95 | 0.95 | 0.90 | — | 1.40 | 1.71 | — | — |
| Cash Ratio | 0.82 | 0.82 | 0.68 | — | 1.00 | 1.05 | — | — |
| Asset Turnover | — | 1.85 | 1.90 | 1.63 | 0.91 | 0.58 | 0.26 | 0.41 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.3% | — | 0.7% | — | — | — | — | — |
| FCF Yield | 53.0% | 28.1% | 26.6% | — | 67.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $262M | $266M | $222M | $212M | $179M | $239M | $239M |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OSCR stock.
Oscar Health, Inc.'s current P/E ratio is 12.1x. The historical average is 140.4x.
Oscar Health, Inc.'s current EV/EBITDA is 5.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 26.2x.
Oscar Health, Inc.'s return on equity (ROE) is -44.4%. The historical average is -31.6%.
Based on historical data, Oscar Health, Inc. is trading at a P/E of 12.1x. Compare with industry peers and growth rates for a complete picture.
Oscar Health, Inc. has 14.4% gross margin and -3.4% operating margin.
Key Metrics
Top Statement Risk
Volatile quarterly combined ratio
Metrics are mathematically derived from official filings.
Premium Multiple Outruns Trailing Returns
Based on reported figures, OSCR trades at 8.55x book value and 12.93x trailing earnings, a premium that implies returns well above the current -44.4% ROE the market has yet to see confirmed in underwriting results.
A price-to-book of 8.55 is high for a managed care carrier, and far above insurance peers such as Arch Capital at 1.70, implying the market is valuing OSCR more like a technology platform than an insurer. The trailing P/E of 12.93 looks reasonable only because recent quarterly earnings were lifted by a strong first-quarter result, so the multiple may be flattered by timing rather than durable underwriting strength. Investors should monitor whether ROE can move from the 51.3% quarterly spike toward a repeatable level, since the current premium depends on that conversion.
Combined Ratio Swings Expose Reserve Sensitivity
As reported in financial statements, OSCR's combined ratio fell from 111.9% in 2025Q4 to 84.8% in 2026Q1 before rising to 96.5% in 2026Q3, moving the book in and out of underwriting profit within two quarters.
The combined ratio has crossed the 100% threshold repeatedly, with the loss ratio ranging from 69.5% to 93.4% across the period, which suggests medical cost estimates and risk adjustment true-ups are driving large quarterly swings. A 96.5% combined ratio in the latest quarter indicates thin underwriting margin rather than a structural cushion. The pattern warrants further investigation into whether the 2026Q1 underwriting profit reflects durable pricing or favorable reserve timing.
Float Income Cannot Offset Underwriting Losses
Based on EDBL's reported figures, OSCR's ROE swung from -35.1% in 2025Q4 to 51.3% in 2026Q1 and back to 7.8% in 2026Q3, with an underwriting margin of 3.5% in the latest quarter providing only modest support.
Because the underwriting margin is only 3.5% in 2026Q3, investment income on float is a larger share of the return than it would be for a steadier underwriter, yet the investment portfolio is not separately disclosed in the supplied data and cannot be quantified. The large ROE swing relative to the modest underwriting margin suggests that a meaningful part of recent profitability may come from non-recurring items. Investors should monitor whether ROE stabilizes once reserve timing effects normalize.
Low Debt Load Masks Thin Equity Cushion
Based on reported figures, OSCR's debt-to-equity ratio of 0.19 in 2026Q3 is conservative, yet equity of $2.2B against $7.8B of liabilities leaves a capital base that rebuilt only after multiple quarters of losses.
A low debt-to-equity ratio reflects limited financial leverage, but for an insurer the more relevant measure is premium-to-surplus, which the supplied data does not report. Statutory risk-based capital ratios are data unavailable and cannot be verified here, so the capacity to absorb a loss-ratio shock cannot be confirmed. The recovery in equity from about $1.0B to $2.2B appears to depend on a few strong quarters, warranting caution about how durable the capital base is.
Premium Valuation Versus Tech-Adjacent Peers
Based on reported peer data, OSCR's 8.55x P/B sits near Alignment Healthcare's 8.28x and far above Arch Capital's 1.70x, while OSCR's 2026Q3 ROE of 7.8% lags the 18.3% achieved by Arch Capital.
OSCR's valuation aligns more closely with the tech-enabled peer ALHC than with traditional insurers, which suggests the market is pricing in a platform or data-distribution thesis rather than insurance underwriting quality. Its return on equity is weaker than Arch's and its net margin is volatile, so the multiple premium is not supported by current profitability on a peer-relative basis. The premium is justified only if the +Oscar platform and cost-to-serve advantages translate into sustained margin expansion.
Quarterly Combined Ratio Masks Reserve Effects
The combined ratio most commonly misapplied to OSCR is the single-quarter figure, which the 84.8% reading in 2026Q1 and 96.5% in 2026Q3 may overstate or understate underlying underwriting strength depending on reserve and risk adjustment timing.
Reading the combined ratio quarter by quarter treats medical cost estimates and risk adjustment true-ups as if they were recurring performance, when the swing from 111.9% to 84.8% within two quarters suggests much of the movement is timing rather than structural change. A trailing-twelve-month combined ratio, paired with reserve development disclosures where available, would give a steadier read on underwriting margin. Investors should monitor whether the 96.5% level holds once favorable prior-period development fades, since that is the figure most likely to be mistaken for durable profitability.